SNN on NYSE

Smith & Nephew

Logo: Smith & Newphew, Public domain, via Wikimedia Commons4

Medical equipment manufacturing company based in Watford, England

Smith & Nephew plc, also known as Smith+Nephew, is a British multinational medical equipment manufacturing company headquartered in Watford, England. It is an international producer of advanced wound management products, arthroscopy products, trauma and clinical therapy products, and orthopaedic reconstruction products.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 16, 2026.

Overview

$625.0MNet income, fiscal 20255
1856Founded1

Compare with Align Technology, Steris or Edwards Lifesciences, or pick any stock.

  • TickerSNN on NYSE1
  • Industrymedical technology industry1
  • HeadquartersLondon1
  • Founded inKingston upon Hull1
  • Websitewww.smith-nephew.com
  • Legal formprivate company limited by shares, public limited company1
  • Listed onLondon Stock Exchange (SN), New York Stock Exchange (SNN)1
  • Business addressBuilding 5, Croxley Park, Hatters Lane, Watford, Hertfordshire, Wd18 8Ye6
  • Filer categoryLarge accelerated filer6
Hull-site-oct-2024
Photo: Clive-Piston, CC BY-SA 4.0, via Wikimedia Commons7

Smith & Nephew plc, also known as Smith+Nephew, is a British multinational medical equipment manufacturing company headquartered in Watford, England. It is an international producer of advanced wound management products, arthroscopy products, trauma and clinical therapy products, and orthopaedic reconstruction products. Its products are sold in over 100 countries. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

11.8%Return on equity5

Financial statements

Gross profit891011125$4.2B in 2025+16% since 2018
0$2.0B$4.0B$6.0B2018: $3.6B$3.6B20182019: $3.8B$3.8B2019+5%2020: $3.2B$3.2B2020−17%2021: $3.7B$3.7B2021+16%2022: $3.7B$3.7B2022+0%2023: $3.8B$3.8B2023+4%2024: $4.0B$4.0B2024+6%2025: $4.2B$4.2B2025+4%
Operating income891011125$794.0M in 2025−8% since 2018
0$250.0M$500.0M$750.0M$1.0B2018: $863.0M$863.0M20182019: $815.0M$815.0M2019−6%2020: $295.0M$295.0M2020−64%2021: $593.0M$593.0M2021+101%2022: $450.0M$450.0M2022−24%2023: $425.0M$425.0M2023−6%2024: $657.0M$657.0M2024+55%2025: $794.0M$794.0M2025+21%
Net income891011125$625.0M in 2025−6% since 2018
0$200.0M$400.0M$600.0M$800.0M2018: $663.0M$663.0M20182019: $600.0M$600.0M2019−10%2020: $448.0M$448.0M2020−25%2021: $524.0M$524.0M2021+17%2022: $223.0M$223.0M2022−57%2023: $263.0M$263.0M2023+18%2024: $412.0M$412.0M2024+57%2025: $625.0M$625.0M2025+52%

Every line of the income statement in the latest annual report, as filed.5

Period ending2025-12-312024-12-312023-12-31
Revenue$6.2B$5.8B$5.5B
Cost of goods sold-$2.0B-$1.8B-$1.7B
Gross profit$4.2B$4.0B$3.8B
Selling, general and administrative expenses-$3.1B-$3.1B-$3.1B
Research and development expenses-$296.0M-$289.0M-$339.0M
Operating profit$794.0M$657.0M$425.0M
Interest income$28.0M$24.0M$34.0M
Interest expense-$140.0M-$145.0M-$132.0M
Other finance costs-$16.0M-$28.0M-$7.0M
Reversal of impairment charge and share of results of associates$113.0M-$10.0M-$30.0M
Profit before taxation$779.0M$498.0M$290.0M
Taxation-$154.0M-$86.0M-$27.0M
Attributable profit for the year$625.0M$412.0M$263.0M
Basic$0.72$0.47$0.30
Diluted$0.72$0.47$0.30

Compare Smith & Nephew with another company

How it started

History

The company was founded in 1856 by Thomas James Smith of Kingston upon Hull who went into business as a dispensing chemist. One early product line that the firm specialised in was cod liver oil; by 1858, it had effectively shifted from retail to wholesale to supply cod liver oil (and other productions) to hospitals, dispensaries, and the wider medical profession.

A few months before his death in 1896, Smith was joined by his nephew, Horatio Nelson Smith, at which point the business became known as T. J. Smith and Nephew. Horatio reoriented the firm from cod liver oil in favour of other products; during 1904, it started producing and supplying bandages and surgical dressings. This new product line experienced high demand following the outbreak of the First World War during 1914, during which its dressings were routinely used to treat wounded soldiers.

It was amid this war that Horatio met with the French President, Raymond Poincaré, after which the company received its largest-ever order after it was awarded a contract valued at £350,000 to supply both surgical and field dressings, which it successfully fulfilled within five months. The firm would ultimately supply the armies of Britain, France, Belgium, Serbia and America, as well as the American Red Cross, during the conflict. The business expanded from 50 to 1,200 staff to fulfil the heavy demands of wartime, but encountered hardship due to a slump in demand that occurred shortly after the conflict's end in 1918.

During the early interwar period, Smith & Nephew was restructured into a professionally-managed multidivisional business. This organisational change came alongside an increased focus on textile-based products, which led to the business diversifying into women’s underwear, first aid kits, and sanitary towels; it also started acquiring licenses to market and produce products such as Gypsona, a plaster-of-paris-based bandage, and the Elastoplast range of bandages. Such product lines provided the basis of the company’s commercial growth throughout the 1920s, 1930s and 1940s.

In 1937, it was listed on the London Stock Exchange. In the aftermath of the Second World War, the company opted to diversify into cosmetics, hypodermic syringes and needles, and pharmaceuticals. During 1951, Smith & Nephew acquired Herts Pharmaceuticals along with its antitubercular treatment and its research department. However, competitive pressure following the entry of large American pharmaceutical companies into the British market led to sales revenue declining throughout the early 1950s.

From Wikipedia’s article on Smith & Nephew, shared under CC BY-SA 4.0.3

Leadership

Who has led Smith & Nephew, and when. Pick a name to see everywhere that person has worked.

Products and brands

  • medical device

Listed on Wikidata.1

Subsidiaries and ownership

Subsidiaries

  • Smith & Nephew (Germany)
  • Smith & Nephew (United States)

From Wikidata.1

Timeline

  1. Nov 1, 2019New chief executive Roland Diggelmann becomes CEO1
  2. May 2018New chief executive Namal Nawana becomes CEO1
  3. 1856Founded Founded in Kingston upon Hull1

Recent filings

  1. Oct 9, 2026S-8
  2. Oct 8, 20266-K NOTICE OF RESULTS
  3. Oct 5, 202625-NSE
  4. Oct 1, 20266-K REDEMPTION PRICE OF $350M 5.150% NOTES DUE 2027
  5. Oct 1, 20266-K TOTAL VOTING RIGHTS
  6. Sep 18, 20266-K REDEMPTION OF $350M 5.150% NOTES DUE 2027
  7. Sep 18, 20266-K ADMISSION TO TRADING
  8. Sep 17, 2026CERT NYSE CERTIFICATION
  9. Sep 16, 20266-K PRICING OF CASH TENDER OFFER FOR 2030 BONDS
  10. Sep 16, 20266-K RESULT OF CASH TENDER OFFER FOR 2030 BONDS
  11. Sep 11, 20266-K
  12. Sep 11, 20268-A12B
  13. Sep 10, 20266-K SMITH+NEPHEW PRICES USD BOND ISSUE
  14. Sep 10, 20266-K
  15. Sep 10, 20266-K

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2